BioPharma Credit PLC
BOPCF
$0.95
$0.077.72%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 36.98M | 36.98M | 41.89M | 41.89M | 35.44M |
| Total Revenue | 36.98M | 36.98M | 41.89M | 41.89M | 35.44M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 36.98M | 36.98M | 41.89M | 41.89M | 35.44M |
| SG&A Expenses | 8.44M | 8.44M | 5.57M | 5.57M | 10.25M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.50K | -5.50K | -62.00K | -62.00K | 20.50K |
| Total Operating Expenses | 8.44M | 8.44M | 5.51M | 5.51M | 10.27M |
| Operating Income | 28.55M | 28.55M | 36.38M | 36.38M | 25.17M |
| Income Before Tax | 28.55M | 28.55M | 36.39M | 36.39M | 25.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 28.55M | 28.55M | 36.39M | 36.39M | 25.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 28.55M | 28.55M | 36.39M | 36.39M | 25.17M |
| EBIT | 28.55M | 28.55M | 36.38M | 36.38M | 25.17M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
| Normalized Basic EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| EPS Diluted | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
| Normalized Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| Average Basic Shares Outstanding | 1.13B | 1.13B | 1.15B | 1.15B | 1.20B |
| Average Diluted Shares Outstanding | 1.13B | 1.13B | 1.15B | 1.15B | 1.20B |
| Dividend Per Share | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Payout Ratio | 69.22% | 69.22% | 55.55% | 55.55% | 32.21% |